Kalbe Farma Tbk PT
F:LCLA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Kalbe Farma Tbk PT (LCLA) under the Base Case is 0.0582 EUR per share.
Compared with the current market price of 0.0305 EUR, the stock appears
Undervalued by 48% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Kalbe Farma Tbk PT Does
PT Kalbe Farma Tbk is one of Indonesia’s largest healthcare companies. It makes and sells prescription medicines, over-the-counter drugs, vitamins, nutritional products, and some medical-related products. Its brands are bought by hospitals, clinics, pharmacies, distributors, and everyday consumers who use its medicines and health supplements at home.
- Headquarters
- Indonesia ID
- Employees
- 12 895
- IPO date
- Jul 30, 1991
Kalbe Farma has no economic moat
Kalbe Farma Tbk PT lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysisBalance Sheet
Continue LCLA Research
Decided on Kalbe Farma? Get an email when LCLA reaches the price you’d buy at. Free with an account.
Other Kalbe Farma listings
What is the Intrinsic Value of one LCLA stock?
The intrinsic value for
Kalbe Farma Tbk PT (LCLA) under the Base Case is 0.0582 EUR.
Is LCLA stock undervalued or overvalued?
Compared with the current market price of 0.0305 EUR, the stock appears Undervalued by 48% .